Details for New Drug Application (NDA): 205525
✉ Email this page to a colleague
NDA 205525 describes SYNDROS, which is a drug marketed by Benuvia and is included in one NDA. There are four patents protecting this drug and two Paragraph IV challenges. Additional details are available on the SYNDROS profile page.
The generic ingredient in SYNDROS is dronabinol. There are eleven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the dronabinol profile page.
The generic ingredient in SYNDROS is dronabinol. There are eleven drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the dronabinol profile page.
Summary for 205525
| Tradename: | SYNDROS |
| Applicant: | Benuvia |
| Ingredient: | dronabinol |
| Patents: | 4 |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 205525
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;ORAL | Strength | 5MG/ML | ||||
| Approval Date: | Mar 23, 2017 | TE: | RLD: | Yes | |||||
| Patent: | See Plans and Pricing | Patent Expiration: | Aug 6, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | See Plans and Pricing | Patent Expiration: | Aug 6, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | See Plans and Pricing | Patent Expiration: | Aug 6, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
Complete Access Available with Subscription
